David A. Enoch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David A. Enoch has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Christianne Micallef
Pharmacy Department, Addenbrooke’s Hospital, Cambridge University Hospital NHS Foundation Trust, Cambridge, UK
10 shared publications Sani H. Aliyu
Cambridge University Hospitals NHS Foundation Trust, UK
4 shared publicationsHuina Yang
Cambridge University Hospitals NHS Foundation Trust, UK
3 shared publicationsN.M. Brown
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Clinical Microbiology & Public Health Laboratory, National Infection Service, Public Health England, Addenbrooke's Hospital, Cambridge, UK
3 shared publicationsS.H. Aliyu
Clinical Microbiology and Public Health Laboratory, National Infection Service, Public Health England, Addenbrooke's Hospital, Cambridge, UK
3 shared publications- Anita Hor-Yun Sung
Pfizer Inc, New York, NY, USA
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Treatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
- 16 September 2026
- Published by Elsevier in eClinicalMedicine
- Vol. 100
Open AccessTreatment and outcome of chronic disseminated candidiasis in the era of antifungal prophylaxis: a retrospective multicentre cohort of 111 patients
- Open Access
- 4 December 2024
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 46, 100688
Refractory fungal infection: Three case reports highlighting good practice
- 4 December 2024
- Published by Elsevier in Medical Mycology Case Reports
- Vol. 46, 100688
Open AccessRefractory fungal infection: Three case reports highlighting good practice
- Open Access
- 13 May 2023
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (5) , 1393-1414
Using Behavior Change Theory to Identify Drivers and Barriers for Antifungal Treatment Decisions: A Case Study in a Large Teaching Hospital in the East of England, UK
Introduction Antifungal stewardship (AFS) programs are recognized to contribute to optimizing antifungal prescribing for treatment and prophylaxis. However, only a small number of such programs are implemented. Consequently, evidence on behavioral drivers and barriers of such programs and learnings from existing successful AFS programs is limited. This study aimed to leverage a large AFS program in the UK and derive learnings from it. The objective was to (a) investigate the impact of the AFS program on prescribing habits, (a) use a Theoretical Domains Framework (TDF) based on the COM-B (Capability, Opportunity, and Motivation for Behavior) to qualitatively identify drivers and barriers for antifungal prescribing behaviors across multiple specialties, and (c) semiquantitatively investigate trends in antifungal prescribing habits over the last 5 years. Methods Qualitative interviews and a semiquantitative online survey were conducted across hematology, intensive care, respiratory, and solid organ transplant clinicians at Cambridge University Hospital. The discussion guide and survey used were developed to identify drivers of prescribing behavior, based on the TDF. Results Responses were received from 21/25 clinicians. Qualitative outcomes demonstrated that the AFS program was effective in supporting optimal antifungal prescribing practices. We found seven TDF domains influencing antifungal prescribing decisions—five drivers and two barriers. The key driver was collective decision-making among the multidisciplinary team (MDT) while key barriers were lack of access to certain therapies and fungal diagnostic capabilities. Furthermore, over the last 5 years and across specialties, we observed an increasing tendency for prescribing to focus on more targeted rather than broad-spectrum antifungals. Conclusions Understanding the basis for linked clinicians’ prescribing behaviors for identified drivers and barriers may inform interventions on AFS programs and contribute to consistently improving antifungal prescribing. Collective decision-making among the MDT may be leveraged to improve clinicians’ antifungal prescribing. These findings may be generalized across specialty care settings.
- 13 May 2023
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 12 (5) , 1393-1414
Open AccessUsing Behavior Change Theory to Identify Drivers and Barriers for Antifungal Treatment Decisions: A Case Study in a Large Teaching Hospital in the East of England, UK
Introduction Antifungal stewardship (AFS) programs are recognized to contribute to optimizing antifungal prescribing for treatment and prophylaxis. However, only a small number of such programs are implemented. Consequently, evidence on behavioral drivers and barriers of such programs and learnings from existing successful AFS programs is limited. This study aimed to leverage a large AFS program in the UK and derive learnings from it. The objective was to (a) investigate the impact of the AFS program on prescribing habits, (a) use a Theoretical Domains Framework (TDF) based on the COM-B (Capability, Opportunity, and Motivation for Behavior) to qualitatively identify drivers and barriers for antifungal prescribing behaviors across multiple specialties, and (c) semiquantitatively investigate trends in antifungal prescribing habits over the last 5 years. Methods Qualitative interviews and a semiquantitative online survey were conducted across hematology, intensive care, respiratory, and solid organ transplant clinicians at Cambridge University Hospital. The discussion guide and survey used were developed to identify drivers of prescribing behavior, based on the TDF. Results Responses were received from 21/25 clinicians. Qualitative outcomes demonstrated that the AFS program was effective in supporting optimal antifungal prescribing practices. We found seven TDF domains influencing antifungal prescribing decisions—five drivers and two barriers. The key driver was collective decision-making among the multidisciplinary team (MDT) while key barriers were lack of access to certain therapies and fungal diagnostic capabilities. Furthermore, over the last 5 years and across specialties, we observed an increasing tendency for prescribing to focus on more targeted rather than broad-spectrum antifungals. Conclusions Understanding the basis for linked clinicians’ prescribing behaviors for identified drivers and barriers may inform interventions on AFS programs and contribute to consistently improving antifungal prescribing. Collective decision-making among the MDT may be leveraged to improve clinicians’ antifungal prescribing. These findings may be generalized across specialty care settings.
- Open Access
- 3 February 2023
- Published by Elsevier in Public Health
- Vol. 217, 89-94
The role of pandemic planning in the management of COVID-19 in England from an infection prevention and control perspective: results of a national survey
- 3 February 2023
- Published by Elsevier in Public Health
- Vol. 217, 89-94
Open AccessThe role of pandemic planning in the management of COVID-19 in England from an infection prevention and control perspective: results of a national survey
- Open Access
- 26 October 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (5) , e0303122
Erratum for Earnshaw et al., “Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom”
- 26 October 2022
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 10 (5) , e0303122
Open AccessErratum for Earnshaw et al., “Real-World Financial and Clinical Impact of Diagnostic-Driven and Empirical-Treatment Strategies in High-Risk Immunocompromised Patients with Suspected Aspergillus Infection in the United Kingdom”
- 16 May 2022
- Published by SAGE Publications in Journal of Infection Prevention
- Vol. 23 (5) , 197-205
Investigation of healthcare-associated SARS-CoV-2 infection: Learning outcomes from an investigative process in the initial phase of the pandemic
Background: Healthcare-associated (HCA) SARS-CoV-2 infection is a significant contributor to the spread of the 2020 pandemic. Timely review of HCA cases is essential to identify learning to inform infection prevention and control (IPC) policies and organisational response. Aim: To identify key areas for improvement through rapid investigation of HCA SARS-CoV-2 cases and to implement change. Methods: Cases were identified based on date of first positive SARS-CoV-2 PCR sample in relation to date of hospital admission. Cases were reviewed using a structured gap analysis tool to identify key learning points. These were discussed in weekly multidisciplinary meetings to gain consensus on learning outcomes, level of harm incurred by the patient and required actions. Learning was then promptly fed back to individual teams and the organisation. Findings: Of the 489 SARS-CoV-2 cases admitted between 10 th March and 23 rd June 2020, 114 suspected HCA cases (23.3%) were reviewed; 58/489 (11.8%) were ultimately deemed to be HCA. Five themes were identified: individual patient vulnerability, communication, IPC implementation, policy issues and organisational response. Adaptations to policies based on these reviews were completed within the course of the initial phase of the pandemic. Conclusion: This approach enabled timely learning and implementation of control measures and policy development.
- 16 May 2022
- Published by SAGE Publications in Journal of Infection Prevention
- Vol. 23 (5) , 197-205
Investigation of healthcare-associated SARS-CoV-2 infection: Learning outcomes from an investigative process in the initial phase of the pandemic
Background: Healthcare-associated (HCA) SARS-CoV-2 infection is a significant contributor to the spread of the 2020 pandemic. Timely review of HCA cases is essential to identify learning to inform infection prevention and control (IPC) policies and organisational response. Aim: To identify key areas for improvement through rapid investigation of HCA SARS-CoV-2 cases and to implement change. Methods: Cases were identified based on date of first positive SARS-CoV-2 PCR sample in relation to date of hospital admission. Cases were reviewed using a structured gap analysis tool to identify key learning points. These were discussed in weekly multidisciplinary meetings to gain consensus on learning outcomes, level of harm incurred by the patient and required actions. Learning was then promptly fed back to individual teams and the organisation. Findings: Of the 489 SARS-CoV-2 cases admitted between 10 th March and 23 rd June 2020, 114 suspected HCA cases (23.3%) were reviewed; 58/489 (11.8%) were ultimately deemed to be HCA. Five themes were identified: individual patient vulnerability, communication, IPC implementation, policy issues and organisational response. Adaptations to policies based on these reviews were completed within the course of the initial phase of the pandemic. Conclusion: This approach enabled timely learning and implementation of control measures and policy development.
- 1 September 2021
- Published by Elsevier in Journal of Infection
- Vol. 83 (3) , e9-e11
The impact of an antifungal stewardship team on voriconazole therapeutic drug monitoring in a UK tertiary hospital
- 1 September 2021
- Published by Elsevier in Journal of Infection
- Vol. 83 (3) , e9-e11
The impact of an antifungal stewardship team on voriconazole therapeutic drug monitoring in a UK tertiary hospital
- Open Access
- 13 March 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (3) , 299
Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study
We aimed to describe the clinical presentation, treatment, outcome and report on factors associated with mortality over a 90-day period in Clostridioides difficile infection (CDI). Descriptive, univariate, and multivariate regression analyses were performed on data collected in a retrospective case-control study conducted in nine hospitals from seven European countries. A total of 624 patients were included, of which 415 were deceased (cases) and 209 were still alive 90 days after a CDI diagnosis (controls). The most common antibiotics used previously in both groups were β-lactams; previous exposure to fluoroquinolones was significantly (p = 0.0004) greater in deceased patients. Multivariate logistic regression showed that the factors independently related with death during CDI were older age, inadequate CDI therapy, cachexia, malignancy, Charlson Index, long-term care, elevated white blood cell count (WBC), C-reactive protein (CRP), bacteraemia, complications, and cognitive impairment. In addition, older age, higher levels of WBC, neutrophil, CRP or creatinine, the presence of malignancy, cognitive impairment, and complications were strongly correlated with shortening the time from CDI diagnosis to death. CDI prevention should be primarily focused on hospitalised elderly people receiving antibiotics. WBC, neutrophil count, CRP, creatinine, albumin and lactate levels should be tested in every hospitalised patient treated for CDI to assess the risk of a fatal outcome.
- 13 March 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (3) , 299
Open AccessMortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study
We aimed to describe the clinical presentation, treatment, outcome and report on factors associated with mortality over a 90-day period in Clostridioides difficile infection (CDI). Descriptive, univariate, and multivariate regression analyses were performed on data collected in a retrospective case-control study conducted in nine hospitals from seven European countries. A total of 624 patients were included, of which 415 were deceased (cases) and 209 were still alive 90 days after a CDI diagnosis (controls). The most common antibiotics used previously in both groups were β-lactams; previous exposure to fluoroquinolones was significantly (p = 0.0004) greater in deceased patients. Multivariate logistic regression showed that the factors independently related with death during CDI were older age, inadequate CDI therapy, cachexia, malignancy, Charlson Index, long-term care, elevated white blood cell count (WBC), C-reactive protein (CRP), bacteraemia, complications, and cognitive impairment. In addition, older age, higher levels of WBC, neutrophil, CRP or creatinine, the presence of malignancy, cognitive impairment, and complications were strongly correlated with shortening the time from CDI diagnosis to death. CDI prevention should be primarily focused on hospitalised elderly people receiving antibiotics. WBC, neutrophil count, CRP, creatinine, albumin and lactate levels should be tested in every hospitalised patient treated for CDI to assess the risk of a fatal outcome.
- Open Access
- 1 December 2020
- Published by Elsevier in Journal of Hospital Infection
- Vol. 106 (4) , 793-803
Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England
- 1 December 2020
- Published by Elsevier in Journal of Hospital Infection
- Vol. 106 (4) , 793-803
Open AccessRisk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England